Human papilloma virus and cervical screening

Current Opinion in Obstetrics and Gynecology

Volumn 15, Issue 6, 2003, Pages 473-477

  Damasus Awatai, Georgette ^a   Freeman Wang, Theresa ^a  

^a WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

Cervical intraepithelial neoplasia (CIN); Cervical screening; Human papilloma virus (HPV)

Indexed keywords

CANCER VACCINE; HUMAN PAPILLOMA VIRUS 16 L1 VIRUS LIKE PARTICLE VACCINE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG; VIRUS DNA;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHLAMYDIA TRACHOMATIS; CIRCUMCISION; COLPOSCOPY; CYTOLOGY; DEVELOPING COUNTRY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG USE; EMERGENCY HEALTH SERVICE; ERADICATION THERAPY; FOLLOW UP; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; IMMUNOGENICITY; INDUSTRIALIZATION; ONCOGENE; PAPANICOLAOU TEST; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SCREENING; SMOKING; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS INFECTION; VIRUS STRAIN; WART VIRUS;

FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIRAL VACCINES;

EID: 1542616697     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200312000-00003     Document Type: Review

References (25)

1. Witt A, Hudelist G, Gregor H, et al. The detection of HPV DNA improves the recognition of cervical intraepithelial lesions. Arch Gynecol Obstet 2003; 268:29-34.
2. Likes WM, Itano J. Human papillomavirus and cervical cancer: not just a sexually transmitted disease. Clin J Oncol Nurs 2002; 7:271-276.
3. Wacholder S. Statistical issues in the design and analysis of studies of human papillomavirus and cervical neoplasia. J Natl Cancer Inst Monogr 2003; 31:125-130.
4. Eosch FX, Franco E, Frazer I, et al. Minireview on HPV, screening and diagnosis of cervical cancer. Int J Cancer (in press)
5. Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
6. Woodman CBJ, Collins S, Rollason TP, et al. Human papillomavirus 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 2003; 361:40-43. This paper suggested that cytological changes associated with HPV-18 infection might understate the severity of underlying disease and this feature should therefore be considered as it could compromise the effectiveness of screening programmes in reducing the frequency of HPV-18 associated cancers.
7. Molano ML, van den Brule AJC, Weiderpass E, et al. The HPV Study Group. Determinants of clearance of HPV infections in women with normal cytology from Colombia. A population-based five-year follow-up study. Am J Epidemiol (in press)
8. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265.
9. Moreno V, Bosch FX, Munoz N, et al. For the IARC Multicentric Cervical Cancer Study Group: effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC Multicentric Case-Control Study. Lancet 2002; 359:1085-1092. This study concluded that long-term use of oral contraceptives could be a cofactor that increases the risk for cervical cancer by up to fourfold in women who are positive for HPV DNA. It recommends that extra effort be made to include this group of women in cervical screening programmes.
10. Smith JS, Green A, de Gonzalez AB, et al. Cervical cancer and the use of hormonal contraceptives: a systematic review. Lancet 2003; 361:1159-1167. This paper acknowledges the increased risk of cervical cancer with long term contraceptive use but suggests that the public health implications of these findings depend largely on the extent to which the observed association remains long after the use of the hormonal contraception has ceased. This, they conclude, could not be evaluated properly from the published data so far.
11. Munoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC Multicentric Case-Control Study. Lancet 2002; 359:1093-1101. This paper concluded that high parity increased the risk of squamous cell carcinoma of the cervix among HPV positive women. A general decline in parity might therefore partly explain the reduction in cervical cancer recently seen in several countries.
12. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346:1105-1112.
13. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programmes. Arch Pathol Lab Med 2003; 127:959-968. This paper concluded that HPV DNA testing was a more sensitive indicator for prevalent high grade CIN than either conventional or liquid based cytology. It observed that one double-negative HPV DNA and Pap test indicated better prognostic assurance against risk of future CIN3 than three subsequent negative conventional Pap tests and may safely allow for the screening interval for such low risk women to be increased.
14. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormality. JAMA 2002; 288:1749-1757.
15. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J Clin Pathol 2002; 55:408-409.
16. Sankaranarayanan R, Wesley R, Thara S, et al. Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer 2003; 106:404-408.
17. Philips Z, Johnson S, Avis M, Whynes DK. Human papillomavirus and the value of screening: young women's knowledge of cervical cancer. Health Educ Res 2003; 18:318-328. This is an interesting paper as it is one of a very few addressing this area.
18. Wright TC, Cox JT, Massad LS, et al. For the 2001 sponsored consensus workshop. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities and cervical cancer precursors. Part 1: Cytological abnormalities. JAMA 2002; 18:2120-2129
19. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomised atypical squamous cells of undetermined significance ASCUS/low grade squamous intraepithelial lesion triage study ALTS. J Natl Cancer Inst 2002; 94:102-107.
20. Crum CP, Berkowitz RS. Human papillomaviruses. Applications, caveats and prevention. J Reprod Med 2002; 47:519-529.
21. Bosch FX, de Sanjose S. Human papillomavirus in cervical cancer. Curr Oncol Rep 2002; 4:175-183. This describes human papillomavirus testing for a triage of women referred because of abnormal smears and a decision analysis considering outcomes and costs.
22. Elfgren K, Jacobs M, Walboomers JM, et al. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002; 100 (5 Pt 1):965-971. The authors provide a useful discussion of the clinical value of HPV as a test of cure.
23. McCaffery K, Forrest S, Waller J, et al. Attitudes towards HPV testing: a qualitative study of beliefs among Pakistani, Indian, African-Caribbean and white women in the U.K. Br J Cancer 2003; 88:42-46.
24. Waller J, McCaffery K, Forrest S, et al. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect 2003; 79:320-322.
25. Koutsky L, Ault K, Wheeler C, et al. A controlled trial of human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651 This is a landmark paper on the development of prophylactic vaccination.